21 January 2026
The following information has been provided:
- Buprenorphine/naloxone (Suboxone®) 2mg/500microgram and 8mg/2mg sublingual tablets were discontinued on 5th January 2026
- various strengths (0.7mg/0.18mg, 1.4mg/0.36mg, 5.7mg/1.4mg, 8.6mg/2.1mg, and 11.4mg/2.9mg) of short-dated buprenorphine/naloxone (Zubsolv®) sublingual tablets are available but future supply to the UK is to be confirmed
- branded and generic buprenorphine sublingual tablets (2mg and 8mg) and buprenorphine oral lyophilisate 2mg and 8mg (Espranor®) remain available.
The Medicine Supply Notification (PDF) provided further details.